Articles 2 www.thelancet.com/diabetes-endocrinology   Published online April 4, 2014   http://dx.doi.org/10.1016/S2213-8587(14)70029-4given glargine, and hypoglycaemia was less frequent.4 An  extension was planned to assess safety and eﬃ   cacy of  exenatide versus glargine during a period of 3 years  (156 weeks) in a controlled setting. A preplanned 84-week interim analysis had similar ﬁ  ndings to the core study. 8  Here, we report the results of the ﬁ  nal 3-year follow-up. Methods Participants DURATION-3 was an open-label randomised trial done between May 13, 2008, and Jan 30, 2012. Patients were enrolled at 72 sites across the USA and Puerto Rico, Europe, Russia, Australia, South Korea, Taiwan, and Mexico. The study design and methods have been reported previously. 4 Eligible patients were aged 18 years  or older, and had type 2 diabetes and suboptimum glycaemic control at screening (HbA 1c 7·1–11·0%